Under Rs 2325 Stocks to Buy in November 2026: 5 Names on the Watchlist
- November 13, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Bajaj Finserv Rs 1,887. Dr Lal Rs 2,009. Narayana Rs 1,840. Phoenix Rs 2,292. Sun Pharma Rs 1,885. NSE closing prices, 12 Nov 2026.
Quick Answer
Five under Rs 2325 stocks to buy on the November 2026 watchlist are Bajaj Finserv, Dr Lal PathLabs, Narayana Hrudayalaya, Phoenix Mills and Sun Pharmaceutical Industries. All five grew revenue in their latest full year, and all five also grew net profit. Bajaj Finserv has the lowest P/E at 12.88, while Dr Lal PathLabs leads on return on equity at 20.13%. Check each valuation against your own risk appetite before acting.
The under Rs 2325 stocks to buy in November 2026 start with five listed names: Bajaj Finserv, Dr Lal PathLabs, Narayana Hrudayalaya, Phoenix Mills and Sun Pharmaceutical Industries. Stocks under Rs 2,325 include a financial services group, a diagnostics chain, a hospital chain, a mall developer and the country’s largest pharma company, priced from about Rs 1,840 to Rs 2,292. Bajaj Finserv is part of the Nifty 50 and Nifty Fin Service indices and Sun Pharmaceutical Industries is part of the Nifty 50 and Nifty Pharma indices.
This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these under Rs 2325 stocks to buy to a portfolio. All prices are NSE closing prices of 12 November 2026, and financials come from company filings.
Click Here – Get Free Investment Predictions
Which Are the Best Under Rs 2325 Stocks to Buy in November 2026?
The best under Rs 2325 stocks to buy in November 2026 for a watchlist are Bajaj Finserv, Dr Lal PathLabs, Narayana Hrudayalaya, Phoenix Mills and Sun Pharmaceutical Industries. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.
| Company | CMP (Rs) | Market Cap | P/E | ROE | Dividend Yield |
|---|---|---|---|---|---|
| Bajaj Finserv | 1,887 | Rs 2,65,782 crore | 12.88 | 12.58% | 0.09% |
| Dr Lal PathLabs | 2,009 | Rs 32,115 crore | 58.78 | 20.13% | 1.07% |
| Narayana Hrudayalaya | 1,840 | Rs 35,033 crore | 42.90 | 17.76% | 0.26% |
| Phoenix Mills | 2,292 | Rs 70,465 crore | 43.23 | 11.14% | 0.13% |
| Sun Pharmaceutical Industries | 1,885 | Rs 4,22,991 crore | 34.91 | 13.74% | 0.91% |
On valuation, Bajaj Finserv and Narayana Hrudayalaya trade below the industry P/E; Dr Lal PathLabs and Sun Pharmaceutical Industries sit close to it; Phoenix Mills carries a premium. Valuation is the first filter for any under Rs 2325 stocks to buy list, and it is covered again in the risk section.
Why These Under Rs 2325 Stocks to Buy Are in Focus
A higher share price does not mean a stock is expensive, because value depends on earnings and the number of shares. The list covers a diversified financial services group, a pathology chain, a hospital chain, a mall developer and the largest pharma company by sales, all of which closed below Rs 2,325 on the NSE on 12 November. Investors searching for the best stocks under Rs 2,325 in India should check earnings, valuation and debt.
Bajaj Finserv: The Lending and Insurance Holding Company Among Under Rs 2325 Stocks to Buy
Bajaj Finserv is the holding company for Bajaj Finance and the Bajaj Allianz insurance businesses. At Rs 1,887, the stock has a market capitalisation of Rs 2,65,782 crore and trades at 12.88 times earnings, while the industry P/E is 16.13.
Reported numbers show FY26 revenue of Rs 1,50,530 crore, up 13.2% year on year, with net profit at Rs 19,669 crore, up 12.0%. The June 2026 quarter added revenue of Rs 42,037 crore (up 19.1%) and net profit of Rs 6,297 crore (up 18.2%).
Return on equity is 12.58%, and the dividend yield is 0.09%. Promoters hold 58.65%, foreign institutions 8.16% and domestic institutions 11.10% as of September 2026.
Dr Lal PathLabs: The Diagnostics Leader Among Under Rs 2325 Stocks to Buy
Dr Lal PathLabs is one of India’s largest diagnostic chains, with a national network of labs and collection centres. Its market capitalisation is Rs 32,115 crore, the share price is Rs 2,009 and the P/E of 58.78 compares with an industry P/E of 61.50.
Over FY26, net profit rose 3.6% to Rs 510 crore on revenue of Rs 2,864 crore, which was up 12.1%. The latest quarter, the June 2026 quarter, brought revenue of Rs 830 crore, up 18.9% year on year, and net profit of Rs 170 crore, up 27.2%.
Return on equity is 20.13%, debt-to-equity is 0.08, and the dividend yield is 1.07%. Promoters hold 52.93%, foreign institutions 18.73% and domestic institutions 21.58% as of September 2026. Domestic institutional holding has risen from 18.49% to 21.58% over the last year.
Check Under Rs 2325 Stocks Live on the Univest Screener
Narayana Hrudayalaya: The Affordable Care Specialist Among Under Rs 2325 Stocks to Buy
Narayana Hrudayalaya is a hospital chain known for affordable cardiac and multi-speciality care. The stock trades at Rs 1,840 with a market capitalisation of Rs 35,033 crore and a P/E of 42.90, against an industry P/E of 61.50.
FY26 revenue rose 43.4% to Rs 7,996 crore and net profit rose 2.6% to Rs 810 crore. In the June 2026 quarter, revenue grew 77.6% year on year to Rs 2,719 crore, while net profit grew 5.4% to Rs 207 crore.
Return on equity is 17.76%, debt-to-equity is 1.29, and the dividend yield is 0.26%. Promoters hold 63.27%, foreign institutions 9.01% and domestic institutions 10.68% as of September 2026. Domestic institutional holding has risen from 7.76% to 10.68% over the last year. A point to keep in view: debt is higher than most names on this list.
Phoenix Mills: The Mall Owner Among Under Rs 2325 Stocks to Buy
Phoenix Mills is a retail-led developer that owns and operates large malls. At Rs 2,292, the stock has a market capitalisation of Rs 70,465 crore and trades at 43.23 times earnings, while the industry P/E is 31.04.
Reported numbers show FY26 revenue of Rs 4,594 crore, up 15.9% year on year, with net profit at Rs 1,557 crore, up 19.6%. The June 2026 quarter added revenue of Rs 1,115 crore (up 13.3%) and net profit of Rs 394 crore (up 23.0%).
Return on equity is 11.14%, debt-to-equity is 0.48, and the dividend yield is 0.13%. Promoters hold 47.24%, foreign institutions 31.62% and domestic institutions 17.31% as of September 2026. Domestic institutional holding has risen from 15.47% to 17.31% over the last year.
Sun Pharmaceutical Industries: The Pharma Heavyweight Among Under Rs 2325 Stocks to Buy
Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with a strong domestic franchise and a growing specialty portfolio in the US. Its market capitalisation is Rs 4,22,991 crore, the share price is Rs 1,885 and the P/E of 34.91 compares with an industry P/E of 37.65.
Over FY26, net profit rose 5.3% to Rs 11,565 crore on revenue of Rs 61,674 crore, which was up 12.7%. The latest quarter, the June 2026 quarter, brought revenue of Rs 16,024 crore, up 11.9% year on year, and net profit of Rs 2,911 crore, up 26.4%.
Return on equity is 13.74%, debt-to-equity is 0.06, and the dividend yield is 0.91%. Promoters hold 52.68%, foreign institutions 14.36% and domestic institutions 22.27% as of September 2026. Domestic institutional holding has risen from 20.23% to 22.27% over the last year.
Download the Univest iOS App or Univest Android App to track these under Rs 2325 stocks live and get daily stock recommendations.
Growth Snapshot: Latest Full Year and Latest Quarter
The table compares year-on-year growth in revenue and net profit for all five under Rs 2325 stocks, using filed results.
| Company | Full-Year Revenue Growth | Full-Year Profit Growth | Latest Quarter | Quarter Revenue Growth | Quarter Profit Growth |
|---|---|---|---|---|---|
| Bajaj Finserv | 13.2% | 12.0% | Jun 2026 | 19.1% | 18.2% |
| Dr Lal PathLabs | 12.1% | 3.6% | Jun 2026 | 18.9% | 27.2% |
| Narayana Hrudayalaya | 43.4% | 2.6% | Jun 2026 | 77.6% | 5.4% |
| Phoenix Mills | 15.9% | 19.6% | Jun 2026 | 13.3% | 23.0% |
| Sun Pharmaceutical Industries | 12.7% | 5.3% | Jun 2026 | 11.9% | 26.4% |
Factors That Move Under Rs 2325 Stocks to Buy
Four factors tend to drive under Rs 2325 stocks, and each one is worth checking before a purchase.
- Earnings growth: Profit should be rising.
- Sector mix: Financial services, diagnostics, hospitals, malls and pharma differ.
- Dividends: Dr Lal PathLabs yields about 1.1%.
- Valuation: P/E runs from about 13 to 59.
Risks to Keep in Mind Before Buying Under Rs 2325 Stocks
The first risk is that a higher share price says little about value, so earnings and valuation matter more. The second is that Dr Lal PathLabs trades at a P/E near 59 while Bajaj Finserv trades near 13, and Bajaj Finserv carries the highest borrowings of the five as a lender. Check results every quarter.
On the numbers, Dr Lal PathLabs trades at the highest P/E on this list at 58.78, so its earnings need to keep growing to support the price. Under Rs 2325 stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.
How to Choose Under Rs 2325 Stocks to Buy
- Look at earnings: Price alone is not a signal.
- Check P/E: Bajaj Finserv trades lowest.
- Read ROE: Dr Lal PathLabs leads.
- Diversify: Spread across the five sectors.
How to Invest in Under Rs 2325 Stocks
- Shortlist two or three companies from this list that match your risk appetite.
- Open the Univest Screener and compare P/E, ROE and debt for each stock.
- Check the latest quarterly results and shareholding pattern on NSE or BSE.
- Decide an amount you can hold for three to five years and split it into two or three purchases.
- Review the holding after every quarterly result instead of reacting to daily price moves.
Conclusion
Bajaj Finserv offers the lowest P/E on this list at 12.88, Dr Lal PathLabs has the highest return on equity at 20.13%, and Phoenix Mills posted the fastest net profit growth in its latest full year at 19.6%. Among the best under Rs 2325 stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these under Rs 2325 stocks to buy.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Under Rs 2325 Stocks to Buy
Which are the best under Rs 2325 stocks to buy in November 2026?
Ans. The five under Rs 2325 stocks on the November 2026 watchlist are Bajaj Finserv, Dr Lal PathLabs, Narayana Hrudayalaya, Phoenix Mills and Sun Pharmaceutical Industries. Bajaj Finserv has the lowest P/E at 12.88, Dr Lal PathLabs has the highest ROE at 20.13%, and Phoenix Mills grew net profit 19.6% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.
Is Sun Pharmaceutical Industries a good stock to buy from this Under Rs 2325 list?
Ans. Sun Pharmaceutical Industries is the largest company on this list with a market capitalisation of Rs 4,22,991 crore and a P/E of 34.91 against an industry P/E of 37.65. Its FY26 revenue rose 12.7% and net profit rose 5.3%, with return on equity at 13.74%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.
Are these under Rs 2325 stocks expensive right now?
Ans. Valuations vary across the group. Bajaj Finserv trades at a P/E of 12.88, Dr Lal PathLabs trades at a P/E of 58.78, Narayana Hrudayalaya trades at a P/E of 42.90, Phoenix Mills trades at a P/E of 43.23, Sun Pharmaceutical Industries trades at a P/E of 34.91, against industry multiples ranging from 16.13 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.
Which of these under Rs 2325 stocks pay a dividend?
Ans. Dividend yields on this list are Bajaj Finserv 0.09%, Dr Lal PathLabs 1.07%, Narayana Hrudayalaya 0.26%, Phoenix Mills 0.13%, Sun Pharmaceutical Industries 0.91%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.
Which stock on this list has the highest return on equity?
Ans. Dr Lal PathLabs has the highest ROE on this list at 20.13%, followed by Narayana Hrudayalaya at 17.76% and Sun Pharmaceutical Industries at 13.74%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.
What are the risks of investing in under Rs 2325 stocks?
Ans. The main risks are price levels that say little about value, a wide spread in valuations and borrowings at the financial group. On this list, Dr Lal PathLabs trades at the highest P/E of 58.78, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.
How can I invest in under Rs 2325 stocks in India?
Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.
